Corporate Magazine 2012 - Boehringer Ingelheim

our businessesperspectives for better healthMICARDIS® PROFILE[ unique chemical structure ][ telmisartan ]micardis® is different to other ARBsas it also contains a non-tetrazolecarboxylic acid ring, shown in red(in chart right). The distinctivegroupings in the structure ofmicardis® give it properties thatmake it different from all other ARBs.TWYNSTA®, MICAMLO®twynsta® is labelled for hypertensivepatients who require intensified bloodpressure control. twynsta® delivers theeffective and prompt blood pressure reductionsneeded to help patients reachtheir goal, and the power of twynsta®lasts for a full 24 hours. twynsta® containstelmisartan, the only ARB with acardiovascular prevention indicationand the calcium channel blocker amlodipine.The TEAMSTA® switch studyTEAMSTA® switch has been a 12-week,open-label, multi-centre study, whichforms part of the telmisartan plus amlodipinephase III/IV clinical trials programme.The results from the TEAMSTA®switch study, presented in 2012, showedthat twynsta® delivers prompt bloodpressure control in the majority of patientswith uncontrolled hypertensionon renin-angiotensin system (RAS)blocker monotherapy and provides furtherconfirmation of its excellent efficacyin controlling high blood pressure.These latest findings add to a robust evidencebase, confirming that twynsta®is a valuable treatment option for patientswith hypertension and is highlyeffective in helping patients who areuncontrolled to reach their blood pressuregoals.OUR LANDMARK TRIALSmicardis® (telmisartan) has beeninvestigated in the most ambitiousand far-reaching research programmeconducted with an arb.In the clinical trial programmesONTARGET, PROTECTION andPROFESS®, over 58,000 patientswere enrolled to investigate theefficacy and cardiovascular protectiveeffects of telmisartan.micardis® (telmisartan) is one ofthe most studied antihypertensivesin clinical trials and is widely usedwith a total of more than 40 million(including micardisplus®)patient-years since approval.Controlling hypertension and cardiovascular protection75